title: Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
abstract: The common dysregulation of the mTOR signaling pathway in tumor cells makes it a key target in oncotherapy. To better understand the effects of mTOR inhibitors, we analyzed 32 published clinical trials on solid tumors other than renal cell cancer, neuroendocrine tumors and metastatic breast cancer, for mTOR inhibitors are already approved by the US FDA to treat the three cancers. A lack of therapeutic effects was observed when mTOR inhibitors were used as a single agent. When combined with other agents, mTOR inhibitors still lacked sufficient clinical activity or just had minimal activity. More studies are required to better understand the clinically effects of mTOR inhibitors and the development of novel mTOR inhibitors is absolutely necessary.
authors.affiliation: 1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China.
authors.forename: Zebo
authors.initials: Z
authors.lastname: Huang
authors.affiliation: 2Department of Oncology, Clinical Medical College of Yangzhou University, No 98 Nantong Western Road, Yangzhou 225001, People's Republic of China.
authors.forename: Yinxia
authors.initials: Y
authors.lastname: Wu
authors.affiliation: 1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China.
authors.forename: Xin
authors.initials: X
authors.lastname: Zhou
authors.affiliation: 1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China.
authors.forename: Jiaqi
authors.initials: J
authors.lastname: Qian
authors.affiliation: 1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhu
authors.affiliation: 1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China.
authors.forename: Yongqian
authors.initials: Y
authors.lastname: Shu
authors.affiliation: 1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, People's Republic of China.
authors.forename: Ping
authors.initials: P
authors.lastname: Liu
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage; D000068338:Everolimus / Q000008:administration & dosage; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011799:Quinazolines / Q000008:administration & dosage; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; C557414:cixutumumab; D000068258:Bevacizumab; C515074:ridaforolimus; C401859:temsirolimus; D000068877:Imatinib Mesylate; D000068338:Everolimus; D000069347:Erlotinib Hydrochloride; D058570:TOR Serine-Threonine Kinases; D000077156:Gefitinib; D020123:Sirolimus
keywords: clinical trials; mTOR inhibitor; solid tumor